Eli Lilly gains after lifting annual revenue view

** Eli Lilly LLY.N shares rise 9% to $1,404.50

** The drugmaker lifts FY revenue forecast to $91 bln to $92 bln from prior $85 bln to $87 bln

** Posts Q3 EPS of $7.48 — above estimates of $6.26

** Reports Q3 sales for diabetes drug Mounjaro at $10.72 bln, obesity drug Zepbound at $5.35 bln

** Trims FY EPS view to $35 to $36 from prior $35.50 to $36.50 to factor in research charges from recent acquisitions

** Analysts on avg were expecting 2026 rev of $88.87 bln, EPS of $33.88 - data compiled by LSEG

** Up to last close, stock up ~20% YTD